Taiwan · Delayed Price · Currency is TWD Senhwa Biosciences Company Description
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents.
The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer.
It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma.
In addition, the company develops CX-4945-AV06, a phase II, double blind randomized, controlled study to evaluate the safety and efficacy of CX-4945 in hospitalized adults with COVID-19.
Senhwa Biosciences, Inc. was incorporated in 2012 and is based in New Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jason Huang |
Contact Details
Address: No. 225, Peihsin Road New Taipei City, 23143 Taiwan | |
| Phone | 886 2 8911 9856 |
| Website | senhwabio.com |
Stock Details
| Ticker Symbol | 6492 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006492002 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason Huang M.D. | Acting Chief Executive Officer and Chief Medical Officer |
| Sarah Chang CPA | Executive Vice President, Chief Financial Officer and Accounting Supervisor |
| Joanne Lo Ph.D. | Acting Chief Operating Officer and Business Development Director |